# Venetoclax Combined With Azactidine in the Treatment of ALAL

> **NCT05901974** · PHASE2 · RECRUITING · sponsor: **Sheng-Li Xue, MD** · enrollment: 23 (estimated)

## Conditions studied

- Acute Leukemia of Ambiguous Lineage

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** azactidine

## Key facts

- **NCT ID:** NCT05901974
- **Lead sponsor:** Sheng-Li Xue, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05901974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05901974, "Venetoclax Combined With Azactidine in the Treatment of ALAL". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05901974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*